Advances in the treatment of type 2 diabetes: impact of dulaglutide
Angela M Thompson, Jennifer M TrujilloDepartment of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA Abstract: The purpose of this review is to provide a review of current data of the most recently approved glucagon-like peptide (GLP)-1-receptor agonist, dulaglutide, in the treatment of type 2 diabetes. To complete this, a PubMed search was performed to identify manuscripts published from 1947 to July 2015. The search terms “Trulicity”, “dulaglutide”, and “LY2189265” were utilized, and publications were included if they eva...
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - May 4, 2016 Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Development of a Microsphere-Based System to Facilitate Real-Time Insulin Monitoring
Conclusions:
We have developed a microsphere-based system to rapidly measure levels of insulin and insulin analogs. We have further demonstrated proof of concept that this bead detection system can be implemented in a lab-on-a-chip format, which will be further developed and combined with microdialysis for real-time monitoring of insulin in vivo. (Source: Journal of Diabetes Science and Technology)
Source: Journal of Diabetes Science and Technology - May 2, 2016 Category: Endocrinology Authors: Kahanovitz, L., Seker, E., Marks, R. S., Yarmush, M. L., Konry, T., Russell, S. J. Tags: Original Articles Source Type: research
Cost-effectiveness analysis of dulaglutide compared with insulin glargine add on to insulin lispro in treatment of type 2 diabetes: a us third-party payer perspective
After failure of conventional insulin therapy in patients with type 2 diabetes, basal–bolus insulin treatment is recommended. Recently, few studies have suggested combination of a glucagon like peptide-1 (GLP-1) receptor agonist, such as dulaglutide, with prandial insulin, can be more effective than basal–bolus insulin regimen in achieving goal of diabetes control (HbA1c ≤7∙0%). The aim of this study is to compare the cost- effectiveness of dulaglutide 0.75 mg and 1.5 mg once weekly with bedtime insulin glargine, add-on to prandial insulin lispro for diabetes control of patients who are candidate for basal-bolus in...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M. Nili, W. Wu, A. Kumar Source Type: research
Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus
ConclusionsBoth insulin intensification strategies led to improved glycemic control in a small group of East Asian and Caucasian patients, who were not adequately controlled on insulin glargine plus metformin and/or pioglitazone. (Source: Journal of Diabetes)
Source: Journal of Diabetes - April 30, 2016 Category: Endocrinology Authors: In‐Kyung Jeong, Choon Hee Chung, 0 Zhiguang Zhou, Jeong Hee Han, Ran Duan, Diana M. Edralin, Angel Rodriguez Tags: Original Article Source Type: research
Impact of diet on the efficacy of insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in East Asian patients with type 2 diabetes: subgroup analysis of the CLASSIFY randomized trial
ConclusionsGlycemic control improved in both LM25 and LM50 groups, but LM50 was significantly more efficacious under certain dietary conditions, particularly with increased carbohydrate intake.ClinicalTrials. gov identifier: NCT01773473; Funding: Eli Lilly.This article is protected by copyright. All rights reserved. (Source: Journal of Diabetes Investigation)
Source: Journal of Diabetes Investigation - April 30, 2016 Category: Endocrinology Authors: Wei Chen, Lei Qian, Hirotaka Watada, Peng Fei Li, Noriyuki Iwamoto, Makoto Imori, Wen Ying Yang Tags: Clinical Trial Source Type: research
A simple dilute and shoot methodology for the identification and quantification of illegal insulin
Publication date: Available online 22 April 2016 Source:Journal of Pharmaceutical Analysis Author(s): Celine. Vanhee, Steven Janvier, Goedele Moens, Eric Deconinck, Patricia Courselle The occurrence of illegal medicines is a well-established global problem and concerns mostly small molecules. However, due to the advances in genomics and recombinant expression technologies there is an increased development of polypeptide therapeutics. Insulin is one of the best known polypeptide drug and illegal versions of this medicine have already led to lethal incidents in the past. Therefore it is crucial for the public h...
Source: Journal of Pharmaceutical Analysis - April 21, 2016 Category: Drugs & Pharmacology Source Type: research
Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
Abstract
This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (<30, 30–35, and >35 kg/m2) with treatment effects of exenatide twice daily (BID) among patients with type 2 diabetes. Patients received exenatide BID added to insulin glargine in two 30‐week studies (exenatide BID vs insulin lispro, N = 627; exenatide BID vs placebo, N = 259). No relationship of baseline BMI with changes in efficacy parameters was observed. HbA1c reductions were significant (p<0.0001) and similar across BMI range groups in the lis...
Source: Diabetes, Obesity and Metabolism - March 28, 2016 Category: Endocrinology Authors: Bruce H.R. Wolffenbuttel, Luc Van Gaal, Santiago Duran Garcia, Jenny Han Tags: RESEARCH LETTER Source Type: research
A case of local delayed-type allergy to zinc-containing insulin as a cause of diabetic ketoacidosis in a patient with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion
Abstract
We herein report a case involving a woman with type 1 diabetes and a history of metal allergy who developed a local delayed-type (type IV) allergy to zinc-containing insulin. She had been treated by continuous subcutaneous insulin infusion, but her glycemic control was poor, and she developed diabetic ketoacidosis. Her plasma insulin concentration was unexpectedly low during use of insulin lispro, but it was recovered by changing from the zinc-containing insulin lispro to the zinc-free insulin glulisine. Intradermal tests showed no reactions to various insulins except for zinc chloride. A skin bi...
Source: Diabetology International - March 15, 2016 Category: Endocrinology Source Type: research
Efficacy and safety of a premixed versus a basal-plus insulin regimen as intensification for type 2 diabetes by timing of the main meal.
CONCLUSIONS: Glycaemic control improved in patients receiving either LM25 or IGL, irrespective of main meal timing. Both regimens can be used in patients with inadequate glycaemic control who are in need of insulin intensification.
PMID: 26934128 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 6, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
New Insulin Preparations: Potential Benefits and Risk Assessments
Concentrated insulins have been especially problematic high alert medications. On February 25, 2015 Federal Drug Administration (FDA) approval made available insulin glargine, Toujeo® U-300 (300 units/ml) in a SoloSTAR® pen. On May 27, 2015 the FDA approved insulin lispro, Humalog® U-200 (200 units/ml) KwikPen™. Increased incidence of insulin resistant type 2 diabetes has escalated the need for concentrated insulin. This paper discusses each insulin, appropriate patient selection, benefits of the new insulins for people with diabetes and providers, and suggestions for prevention of potential off-label use of insulin p...
Source: The Journal for Nurse Practitioners - February 27, 2016 Category: Nursing Authors: Dana E. Brackney Tags: Feature Article Source Type: research
Converting U-500 regular insulin to insulin detemir and insulin lispro in a patient undergoing dietary changes in preparation for bariatric surgery.
CONCLUSION: Subcutaneous insulin therapy in a woman preparing for bariatric surgery was safely converted from U-500R to basal therapy with U-100 insulin detemir and with as-needed boluses of U-100 insulin lispro. This occurred as the patient switched from a regular diet to a low-calorie, high-protein diet.
PMID: 26896501 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - February 22, 2016 Category: Drugs & Pharmacology Authors: Nguyen KV, Weidner JA, Shaw KF, Valdez CA Tags: Am J Health Syst Pharm Source Type: research
Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.
CONCLUSIONS: Albiglutide represents a reasonable treatment option for patients with type 2 diabetes based on its cost-utility, relative to insulin lispro, insulin glargine, and sitagliptin.
PMID: 26882484 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 19, 2016 Category: Health Management Tags: J Med Econ Source Type: research
Pharmacokinetics and pharmacodynamics of insulin glargine–insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
Conclusions Glargine/glulisine pharmacokinetics in type 1 diabetes can closely approximate physiologic insulin responses in healthy individuals during a day in which three standardized meals are consumed. Additionally, when glulisine is dosed only five minutes pre-meal, systemic insulin concentration rises as rapidly as prandial endogenous insulin levels. This present study compared glargine and glulisine administered in an approximate 50/50 proportion. Future studies of alternate meal times, meal content and differing premixed insulin preparations are indicated. (Source: Journal of Clinical and Translational Endocrinology)
Source: Journal of Clinical and Translational Endocrinology - February 9, 2016 Category: Endocrinology Source Type: research
U-200 Humalog Insulin Now Available in United States
No abstract available (Source: Home Healthcare Nurse)
Source: Home Healthcare Nurse - February 1, 2016 Category: Nursing Tags: Focus on Diabetes Source Type: research
A high-throughput mass spectrometry assay to simultaneously measure intact insulin and C-peptide.
CONCLUSION: We developed and validated a high-throughput, quantitative, multiplexed LC-MS/MS assay for intact insulin and C-peptide.
PMID: 26820765 [PubMed - as supplied by publisher] (Source: International Journal of Clinical Chemistry)
Source: International Journal of Clinical Chemistry - January 25, 2016 Category: Chemistry Authors: Taylor SW, Clarke NJ, Chen Z, McPhaul MJ Tags: Clin Chim Acta Source Type: research
